<DOC>
	<DOCNO>NCT00595426</DOCNO>
	<brief_summary>To evaluate safety efficacy twice daily dose daily dose YM150 subject undergo primary elective knee replacement surgery</brief_summary>
	<brief_title>A Study Evaluate Safety Efficacy YM150 Patients With Knee Replacement Surgery</brief_title>
	<detailed_description />
	<mesh_term>Darexaban</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Subject schedule elective primary knee arthroplasty Written Informed consent obtain Subject document history previous VTE Subject consider increase risk VTE Subject active bleeding condition associate increase risk bleeding Subject planning surgery contralateral knee time within 6 week enrollment study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>Knee Arthroplasty</keyword>
	<keyword>Factor Xa</keyword>
	<keyword>VTE</keyword>
	<keyword>Thrombosis</keyword>
	<keyword>Anticoagulants</keyword>
</DOC>